Updated:
i2o Therapeutics
i2O Therapeutics is a biotechnology company founded in 2019 in Cambridge, Massachusetts. It focuses on developing delivery platforms and medicines using ionic...
i2o Therapeutics
i2O Therapeutics is a biotechnology company founded in 2019 in Cambridge, Massachusetts. It focuses on developing delivery platforms and medicines using ionic liquid technology. The company aims to enhance patient outcomes by enabling the oral delivery of peptides, proteins, and other injection-based drugs.
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Cambridge
Corporate office
Cambridge, MA, United States
Sector focus
Frequently asked questions
Who runs investment decisions at i2o Therapeutics?
Investment decisions are made by the family office principals, but no named investment professionals are publicly listed. The firm's website (i2obio.com) does not disclose a leadership team.
How does i2o Therapeutics source proprietary deal flow?
The firm likely sources deals through academic partnerships and founder relationships in the rare-disease and ion-channel biology space, given its location in Cambridge's biotech cluster. No specific sourcing model is confirmed.
Is i2o Therapeutics structured as a single family office or does it operate more like a venture firm?
It is structured as a single-family office, meaning it invests the capital of one family rather than raising external LP commitments. This allows longer hold periods than traditional VC.
Does i2o Therapeutics participate in fund commitments or only direct deals?
The firm appears to focus on direct investments in biotech companies. No evidence of fund-of-funds or external GP commitments has been observed.
What investment stages does i2o Therapeutics typically target?
Based on its profile, i2o Therapeutics likely targets early-stage therapeutic companies, from preclinical to Phase II clinical trials. Exact stage preferences are not public.
Which sectors does i2o Therapeutics explicitly avoid?
The firm does not publicly disclose sectors it avoids. Given its biotech focus, it likely excludes non-bio sectors like real estate or technology.
Where does the underlying wealth come from?
The underlying wealth origin is not publicly disclosed. The firm's name and investment focus do not reveal a specific industry source.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: